TuHURA Biosciences
HURA
24 hedge funds and large institutions have $4.65M invested in TuHURA Biosciences in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 7 closing their positions.
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
0% more funds holding
Funds holding: 24 → 24 (0)
0% more ownership
Funds ownership: 0% → 0.01% (+0%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
26% less capital invested
Capital invested by funds: $6.31M → $4.65M (-$1.67M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.05M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$704K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$210K |
| 4 |
Two Sigma Investments
New York
|
+$81.4K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$104K |
| 2 |
PVI
Pura Vida Investments
New York
|
-$64K |
| 3 |
VF
Virtu Financial
New York
|
-$60.4K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$44K |
| 5 |
Two Sigma Advisers
New York
|
-$23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citadel Advisors
Miami,
Florida
| – | -$104K | -26 | Closed |
|
|
PVI
27
Pura Vida Investments
New York
| – | -$64K | -16 | Closed |
|
|
28
Envestnet Asset Management
Chicago,
Illinois
| – | -$44K | -11 | Closed |
|
|
29
Two Sigma Advisers
New York
| – | -$23K | -6 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$7K | -2 | Closed |
|
|
FEG
31
Financial Enhancement Group
Anderson,
Indiana
| – | -$3K | -1 | Closed |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | – | – |
|
|
EVM
33
Eaton Vance Management
Boston,
Massachusetts
| – | +$15.8K | +6 | New |
|
HURA Hedge Fund Activity: Q3 2021 in Review
24 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in TuHURA Biosciences (HURA) for Q3 2021, worth a combined $4.65M — down 26% from $6.31M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new HURA positions and 7 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.05M. The largest seller was Citadel Advisors, exiting entirely with an estimated $104K sold.
- 24 institutional investors held TuHURA Biosciences (HURA) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $4.65M of TuHURA Biosciences stock for Q3 2021, down 26% quarter-over-quarter.
- 8 funds opened new TuHURA Biosciences positions in Q3 2021 and 7 closed out, a net change of +1 holder.
- The largest TuHURA Biosciences buyer in Q3 2021 was Armistice Capital, an estimated $3.05M added.
- The largest TuHURA Biosciences seller in Q3 2021 was Citadel Advisors, an estimated $104K sold.
Based on aggregated 13F filings for Q3 2021.